|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanderson RD, Yang Y, Suva LJ and Kelly T:
Heparan sulfate proteoglycans and heparanase - partners in
osteolytic tumor growth and metastasis. Matrix Biol. 23:341–352.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Simizu S, Ishida K and Osada H: Heparanase
as a molecular target of cancer chemotherapy. Cancer Sci.
95:553–558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Edovitsky E, Elkin M, Zcharia E, Peretz T
and Vlodavsky I: Heparanase gene silencing, tumor invasiveness,
angiogenesis, and metastasis. J Natl Cancer Inst. 96:1219–1230.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng L, Jiang G, Mei H, et al: Small RNA
interference-mediated gene silencing of heparanase abolishes the
invasion, metastasis and angiogenesis of gastric cancer cells. BMC
Cancer. 10:332010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lerner I, Baraz L, Pikarsky E, et al:
Function of heparanase in prostate tumorigenesis: potential for
therapy. Clin Cancer Res. 14:668–676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bar-Sela G, Kaplan-Cohen V, Ilan N,
Vlodavsky I and Ben-Izhak O: Heparanase expression in
nasopharyngeal carcinoma inversely correlates with patient
survival. Histopathology. 49:188–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ogren S and Lindahl U: Cleavage of
macromolecular heparin by an enzyme from mouse mastocytoma. J Biol
Chem. 250:2690–2697. 1975.PubMed/NCBI
|
|
10
|
Nakajima M, Irimura T, Di Ferrante D, Di
Ferrante N and Nicolson GL: Heparan sulfate degradation: relation
to tumor invasive and metastatic properties of mouse B16 melanoma
sublines. Science. 220:611–613. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y
and Schirrmacher V: Lymphoma cell-mediated degradation of sulfated
proteoglycans in the subendothelial extracellular matrix:
relationship to tumor cell metastasis. Cancer Res. 43:2704–2711.
1983.PubMed/NCBI
|
|
12
|
Ilan N, Elkin M and Vlodavsky I:
Regulation, function and clinical significance of heparanase in
cancer metastasis and angiogenesis. Int J Biochem Cell Biol.
38:2018–2039. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vreys V and David G: Mammalian heparanase:
what is the message? J Cell Mol Med. 11:427–452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao W, Wang XS, Niu HT, Wang LL, Han BM
and Xia SJ: Clinical relevance of heparanase mRNA expression in
bladder cancer and its usefulness as a detection marker in voided
urine. Mol Med Rep. 2:327–331. 2009.PubMed/NCBI
|
|
15
|
Nobuhisa T, Naomoto Y, Ohkawa T, et al:
Heparanase expression correlates with malignant potential in human
colon cancer. J Cancer Res Clin Oncol. 131:229–237. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen JQ, Zhan WH, He YL, et al:
Relationship between heparanase mRNA expression in human gastric
cancer and its clinicopathological features. Zhonghua Zhong Liu Za
Zhi. 26:609–611. 2004.(In Chinese).
|
|
17
|
Theodoro TR, de Matos LL, Sant AA, et al:
Heparanase expression in circulating lymphocytes of breast cancer
patients depends on the presence of the primary tumor and/or
systemic metastasis. Neoplasia. 9:504–510. 2007. View Article : Google Scholar
|
|
18
|
Leiser Y, Abu-El-Naaj I, Sabo E, et al:
Prognostic value of heparanase expression and cellular localization
in oral cancer. Head Neck. 33:871–877. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brun R, Naroditsky I, Waterman M, et al:
Heparanase expression by Barrett’s epithelium and during esophageal
carcinoma progression. Mod Pathol. 22:1548–1554. 2009.
|
|
20
|
Quiros RM, Rao G, Plate J, et al: Elevated
serum heparanase-1 levels in patients with pancreatic carcinoma are
associated with poor survival. Cancer. 106:532–540. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong X, Nelson KK, DeCarvalho AC and
Kalkanis SN: Heparanase expression of glioma in human and animal
models. J Neurosurg. 113:261–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelly T, Miao HQ, Yang Y, et al: High
heparanase activity in multiple myeloma is associated with elevated
microvessel density. Cancer Res. 63:8749–8756. 2003.PubMed/NCBI
|
|
23
|
Bitan M, Polliack A, Zecchina G, et al:
Heparanase expression in human leukemias is restricted to acute
myeloid leukemias. Exp Hematol. 30:34–41. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakajima M, DeChavigny A, Johnson CE,
Hamada J, Stein CA and Nicolson GL: Suramin. A potent inhibitor of
melanoma heparanase and invasion. J Biol Chem. 266:9661–9666.
1991.PubMed/NCBI
|
|
25
|
Miao HQ, Liu H, Navarro E, Kussie P and
Zhu Z: Development of heparanase inhibitors for anti-cancer
therapy. Curr Med Chem. 13:2101–2111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miao HQ, Elkin M, Aingorn E,
Ishai-Michaeli R, Stein CA and Vlodavsky I: Inhibition of
heparanase activity and tumor metastasis by laminarin sulfate and
synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer.
83:424–431. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karoli T, Liu L, Fairweather JK, et al:
Synthesis, biological activity, and preliminary pharmacokinetic
evaluation of analogues of a phosphosulfomannan angiogenesis
inhibitor (PI-88). J Med Chem. 48:8229–8236. 2005. View Article : Google Scholar
|
|
28
|
Fjose A, Ellingsen S, Wargelius A and Seo
HC: RNA interference: mechanisms and applications. Biotechnol Annu
Rev. 7:31–57. 2001. View Article : Google Scholar
|
|
29
|
Zhang ZH, Chen Y, Zhao HJ, Xie CY, Ding J
and Hou YT: Silencing of heparanase by siRNA inhibits tumor
metastasis and angiogenesis of human breast cancer in vitro and in
vivo. Cancer Biol Ther. 6:587–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Li L, Wang Y, et al:
Downregulating the expression of heparanase inhibits the invasion,
angiogenesis and metastasis of human hepatocellular carcinoma.
Biochem Biophys Res Commun. 358:124–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang G, Zheng L, Pu J, et al: Small RNAs
targeting transcription start site induce heparanase silencing
through interference with transcription initiation in human cancer
cells. PLoS One. 7:e313792012. View Article : Google Scholar
|
|
32
|
De Luca A, Maiello MR, D’Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012.PubMed/NCBI
|
